treatment | Page 59 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

treatment

Tamibarotene

Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL) .

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Key Points
In patients with RR-AML, venetoclax combination therapy resulted in responses in 31% of patients and a median OS of 6.1 months.

NPM1 mutations predicted higher response rates; adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 predicted worse OS.

Robert Hasserjian, MD

Hasserjian, Robert
Director, Hematopathology Fellowship Program
Massachusetts General Hospital

Dr. Hasserjian's clinical work and research focus on myeloid neoplasia.  He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.